Is Apellis Pharmaceuticals’ FDA Win Just the Beginning?

When Apellis Pharmaceuticals (APLS) secured FDA approval for EMPAVELI in C3 glomerulopathy and IC-MPGN last summer, the stock was trading near $28. Today it sits at $19.96, down 31% over the past year. That disconnect reveals the gap between regulatory wins and commercial execution.

The bull case starts with the label. EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That’s roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.

Management guided for 225 cumulative patient start forms by year-end 2025. They hit 152 by September’s close. The math: that’s 76 forms per month in July-August, implying just 24 per month in Q4 if they hit guidance. CEO Cedric Francois framed this as working through “the onetime wave of early adopters,” expecting “steady, consistent growth going into next year.” The bolus is over, and the ramp will be gradual.

The bear case centers on SYFOVRE, which accounts for the bulk of revenue. Q3 2025 brought $151 million in sales, flat versus Q2’s $161 million. Injection growth was just 4%, “driven predominantly by free goods” that cost the company $15 million in the quarter. New patient share ticked down to 52%, and management openly acknowledged retina specialists are taking a “wait-and-see approach” despite SYFOVRE’s 60% market share.

The patient access crisis is structural. CFO Tim Sullivan admitted on the Q3 call:

We do see a significant headwind for these patients who are trying to get treated and want to get treated, but can’t afford it. Many retina specialists are not treating GA patients or not even having the conversation they should be having.

When Good Days Foundation stopped accepting new co-pay assistance applications, practices stopped enrolling new patients. Competitor Astellas cut IZERVAY guidance by $200 million for the same reason. This isn’t an Apellis problem; it’s a geographic atrophy market problem.

The verdict: this isn’t an inflection point yet. The FDA win opened the door, but commercial execution is lagging. At 57x trailing earnings and 46x forward earnings, the market is pricing in aggressive growth that the launch trajectory doesn’t support. EMPAVELI’s rare disease economics are real, but 24 patient starts per month won’t move the needle on a $2.6 billion market cap. If you believe the European launch accelerates adoption and SYFOVRE’s access issues resolve over 12-18 months, there’s a case for the $34.78 analyst target. But management is selling into weakness while guiding to “steady, measured” growth. That’s not breakthrough language. That’s survival mode.